Exagen Inc (XGN)
1.97
+0.05
(+2.60%)
USD |
NASDAQ |
Jun 20, 16:00
1.95
-0.02
(-1.02%)
After-Hours: 20:00
Exagen Enterprise Value: 25.63M for June 18, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| June 18, 2024 | 25.63M |
| June 17, 2024 | 27.71M |
| June 14, 2024 | 26.32M |
| June 13, 2024 | 26.67M |
| June 12, 2024 | 26.50M |
| June 11, 2024 | 27.36M |
| June 10, 2024 | 26.84M |
| June 07, 2024 | 27.36M |
| June 06, 2024 | 27.71M |
| June 05, 2024 | 27.89M |
| June 04, 2024 | 26.32M |
| June 03, 2024 | 26.50M |
| May 31, 2024 | 26.15M |
| May 30, 2024 | 25.63M |
| May 29, 2024 | 25.45M |
| May 28, 2024 | 25.89M |
| May 24, 2024 | 24.58M |
| May 23, 2024 | 27.02M |
| May 22, 2024 | 24.76M |
| May 21, 2024 | 25.28M |
| May 20, 2024 | 24.76M |
| May 17, 2024 | 24.93M |
| May 16, 2024 | 25.11M |
| May 15, 2024 | 25.45M |
| May 14, 2024 | 22.85M |
| Date | Value |
|---|---|
| May 13, 2024 | 20.76M |
| May 10, 2024 | 19.55M |
| May 09, 2024 | 16.77M |
| May 08, 2024 | 16.57M |
| May 07, 2024 | 15.88M |
| May 06, 2024 | 16.22M |
| May 03, 2024 | 16.57M |
| May 02, 2024 | 16.31M |
| May 01, 2024 | 15.88M |
| April 30, 2024 | 16.32M |
| April 29, 2024 | 16.74M |
| April 26, 2024 | 16.78M |
| April 25, 2024 | 16.74M |
| April 24, 2024 | 16.22M |
| April 23, 2024 | 16.57M |
| April 22, 2024 | 16.57M |
| April 19, 2024 | 16.05M |
| April 18, 2024 | 17.07M |
| April 17, 2024 | 16.57M |
| April 16, 2024 | 17.19M |
| April 15, 2024 | 17.09M |
| April 12, 2024 | 17.90M |
| April 11, 2024 | 17.99M |
| April 10, 2024 | 17.73M |
| April 09, 2024 | 18.25M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-6.454M
Minimum
Nov 14 2022
343.69M
Maximum
Sep 19 2019
88.42M
Average
72.23M
Median
Feb 16 2022
Enterprise Value Benchmarks
| Fonar Corp | 35.86M |
| XWELL Inc | -3.505M |
| ProPhase Labs Inc | 97.30M |
| Applied DNA Sciences Inc | -2.829M |
| Veracyte Inc | 1.454B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -3.36M |
| Revenue (Quarterly) | 14.42M |
| Total Expenses (Quarterly) | 17.42M |
| EPS Diluted (Quarterly) | -0.19 |
| Gross Profit Margin (Quarterly) | 59.65% |
| Profit Margin (Quarterly) | -23.31% |
| Earnings Yield | -55.90% |
| Normalized Earnings Yield | -55.90 |